Research Protocol

IGF-1 LR3 (1mg) — Research Protocol

Dosage Calculator → How to Reconstitute →

Quickstart Highlights

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects[1]. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity[2]. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~0.333 mg/mL concentration (333 mcg/mL).
  • Typical daily range: 20–50 mcg once daily subcutaneously (gradual titration recommended).
  • Easy measuring: At 0.333 mg/mL, 1 unit = 0.01 mL ≈ 3.33 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F) for up to 12 months; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid repeated freeze–thaw cycles.

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~0.333 mg/mL)

Phase Dose Units (per injection)
Weeks 1–2 20 mcg (0.02 mg) 6 units (0.06 mL)
Weeks 3–4 40 mcg (0.04 mg) 12 units (0.12 mL)
Weeks 5–8 50 mcg (0.05 mg) 15 units (0.15 mL)

Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose[3]. This schedule uses the maximum practical dilution (3.0 mL) for clear measurements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall to avoid foaming; do not shake.
  3. Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
  4. Label the vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at −20 °C (−4 °F) for up to 3–6 months[4].

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (IGF-1 LR3, 1 mg each):
    • 8 weeks ≈ 3 vials (~2.24 mg total needed)
    • 12 weeks ≈ 4 vials (~3.64 mg total needed)
    • 16 weeks ≈ 6 vials (~5.04 mg total needed)
  • Insulin Syringes (U-100, 0.5 mL or 1 mL):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
    • 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
    • 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
    • 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes
  • Sharps Container: For safe disposal of used needles and syringes[5].
  • Fast-acting carbohydrate source: Glucose tablets or juice on hand during cycle to address potential hypoglycemia symptoms, especially during dose titration[6].

Protocol Overview

Concise summary of the once-daily subcutaneous regimen.

  • Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability[1].
  • Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods.
  • Dose Range: 20–50 mcg daily with gradual titration; conservative protocols remain at ≤50 mcg/day.
  • Reconstitution: 3.0 mL per 1 mg vial (~0.333 mg/mL or 333 mcg/mL) for precise unit measurements.
  • Storage: Lyophilized powder frozen at −20 °C (−4 °F); reconstituted solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles.
  • Cycling: Common approach is 8 weeks on, 4–8 weeks off to prevent receptor desensitization[7].

Dosing Protocol

Suggested daily titration approach for tolerance assessment.

  • Start (Weeks 1–2): 20 mcg daily to assess tolerance, particularly regarding blood glucose effects[6].
  • Titrate (Weeks 3–4): Increase to 40 mcg daily if Week 1–2 well-tolerated with no significant hypoglycemic symptoms.
  • Maintain (Weeks 5–8): Hold at 50 mcg daily; this is considered the conservative upper end for most research protocols[2].
  • Frequency: Once per day subcutaneously; timing often aligned with meals (morning or post-workout) to manage insulin-like effects.
  • Cycle Length: 8 weeks is standard; 12-week protocols exist but may show diminished returns beyond Week 6–8[7].
  • Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent local irritation or lipohypertrophy[8].

Storage Instructions

Proper storage is critical to maintain peptide stability and potency.

  • Lyophilized (unopened): Store at −20 °C (−4 °F) or colder (−80 °C optimal) in dry, dark conditions for up to 12 months[4]; short-term storage at 2–8 °C (35.6–46.4 °F) for several months is acceptable.
  • Reconstituted solution: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 30 days for optimal potency[9].
  • Extended storage of reconstituted solution: For storage beyond 30 days, prepare sterile aliquots and freeze at −20 °C (−4 °F); aliquots remain stable for 3–6 months[4]. Never refreeze a thawed vial.
  • Handling: Allow frozen vials to reach room temperature before opening to minimize condensation; always inspect solution for clarity (discard if cloudy or contains particles)[10].
  • Protection: Keep all vials protected from light and maintain cold chain during storage.

How It Works

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins[1]. This modification extends the peptide’s half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability[2].

The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day[11]. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications[12].

Studies examining IGF-1 and its analogs demonstrate effects on cellular growth, protein synthesis, and metabolic regulation. The insulin-like properties of IGF-1 LR3 necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases[6].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature on IGF-1 and its analogs.

Potential Research Observations:

  • Enhanced anabolic signaling and protein synthesis in target tissues[1].
  • Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction[2].
  • Metabolic effects through IGF-1 receptor pathways.

Important Safety Considerations:

  • Hypoglycemia risk: The most significant concern with IGF-1 LR3 is its insulin-like effect on blood glucose; symptoms may include shakiness, confusion, sweating, or dizziness[6]. Always administer with food and monitor for glucose-related symptoms.
  • No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is restricted to research applications[12].
  • Injection site reactions: Mild local irritation, redness, or discomfort may occur; proper technique and site rotation minimize these effects[8].
  • Dose-dependent effects: Safety concerns increase substantially at doses exceeding 50–60 mcg/day; conservative dosing protocols are strongly recommended[2].
  • Receptor desensitization: Continuous use beyond 6–8 weeks may lead to diminished response; cycling protocols (e.g., 8 weeks on, 4–8 weeks off) are commonly employed[7].

Lifestyle Factors

Complementary strategies to support research protocol outcomes.

  • Nutrition: Maintain adequate protein intake (1.6–2.2 g/kg body weight) to support anabolic processes; ensure regular meal timing to manage blood glucose stability.
  • Training: Combine resistance training protocols with appropriate recovery periods; IGF-1 signaling pathways are activated by mechanical loading.
  • Sleep & Recovery: Prioritize 7–9 hours of quality sleep nightly to optimize endogenous growth factor production and tissue repair processes.
  • Hydration: Maintain consistent hydration status to support metabolic function and peptide distribution.
  • Glucose monitoring: Consider periodic blood glucose checks during dose titration, especially if experiencing any hypoglycemic symptoms.

References

For laboratory and research use only. Minimum 98% purity. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. This protocol is provided for educational and research purposes only and is not medical advice. The purchaser accepts full responsibility for safe handling, storage and lawful use.